Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug

Transfusion

Volumn 40, Issue 6, 2000, Pages 663-668

  Cunha, P D ^b   Lord, R S ^b   Johnson, S T ^b   Wilker, P R ^b   Aster, R H ^b   Bougie, Daniel W ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY ETODOLAC; DRUG METABOLITE; ETODOLAC; ETODOLAC GLUCURONIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CONTROLLED STUDY; DRUG CONJUGATION; DRUG METABOLISM; DRUG SENSITIZATION; ERYTHROCYTE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER MICROSOME; LOW BACK PAIN; NONHUMAN; RAT; SERUM; URINALYSIS;

ACUTE DISEASE; ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOIMMUNE DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COOMBS' TEST; DRUG HYPERSENSITIVITY; ETODOLAC; FEMALE; GLUCURONATES; HUMANS; LOW BACK PAIN; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RATS; RECURRENCE;

EID: 0005665808     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40060663.x     Document Type: Article

References (41)

1. Petz LD, Mueller-Eckhardt C. Drug-induced immune hemolytic anemia. Transfusion 1992;32:202-4.
2. Petz LD. Drug-induced autoimmune hemolytic anemia. Transfus Med Rev 1993;7:242-54.
3. Packman CH, Leddy JP. Drug-induced immune hemolytic anemia. In: Beutler E, Lichtman M, Collar BS, Kipps TJ, eds. Hematology. 5th ed. New York: McGraw-Hill, 1995:691-6.
4. Petz LD. Drug-induced immune hemolysis. N Engl J Med 1985;313:510-2.
5. Salama A, Santoso S, Mueller-Eckhardt C. Antigenic determinants responsible for the reactions of drug-dependent antibodies with blood cells. Br J Haematol 1991;78:535-9.
6. Aster RH. Response of thrombocytes to toxic injury. In: Sipes G, McQueen CA, Gandolfi AJ, eds. Comprehenisive toxicology, vol 4. New York: Pergamon, 1997:263-84.
7. Salama A, Kroll H, Wittmann G, Mueller-Eckhardt C. Diclofenac-induced immune haemolytic anaemia: simultaneous occurrence of red blood cell autoantibodies and drug-dependent antibodies. Br J Haematol 1996;95:640-4.
8. Salama A, Mueller-Eckhardt C, Kissel K, et al. Ex vivo antigen preparation for the serological detection of drug-dependent antibodies in immune hemolytic anemias. Br J Haematol 1984;58:525-31.
9. Salama A, Burger M, Mueller-Eckhardt C. Acute immune hemolysis induced by a degradation product in amphotericin B. Blut 1989;58:59-61.
10. Salama A, Gotsche B, Mueller-Eckhardt C. Autoantibodies and drug-or metabolite-dependent antibodies in patients with diclofenac-induced immune haemolysis. Br J Haematol 1991;77:546-9.
11. Bougie D, Johnson ST, Weitekamp LA, Aster RH. Sensitivity to a metabolite of Diclofenac as a cause of acute immune hemolytic anemia. Blood 1997;90:407-13.
12. Radominska-Pyrek A, Zimniak P, Chari M, et al. Glucuronides of monohydrozylated bile acids: specificity of microsomal glucuronyl transferase for the glucuronidation site, C-3 configuration, and side chain length. J Lipid Res 1986;27:89-101.
13. Humber LG, Ferdinandi E, Demerson CA, et al. Etodolac, a novel antiinflammatory agent. The syntheses and biological evaluation of its metabolites. J Med Chem 1988;31:1712-9.
14. Berendes U, Blaschke G. Simultaneous determination of the phase II metabolites of the nonsteroidal anti-inflammatory drug etodolac in human urine. Enantiomer 1996;1:415-22.
15. Sanford-Driscoll M, Knodel LC. Induction of hemolytic anemia by nonsteroidal anti-inflammatory drugs. Drug Intell Clin Pharm 1986;20:925-34.
16. LoBuglio AF, Jandl JH. The nature of the alpha-methyldopa red-cell antibody. N Engl J Med 1967;276:658-65.
17. Kleinman S, Nelson R, Pharm D, et al. Positive direct anti-globulin tests and immune hemolytic anemia in patients receiving procainamide. N Engl J Med 1984;311:809-12.
18. Schwartz RS, Berkman EM, Silverstein LE. The autoimmune hemolytic anemias. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, eds: Hematology. Basic principles and practice. New York: Churchill Livingstone, 1991:422-41.
19. Ehmann WC, Cephalosporin-induced hemolysis: a case report and review of the literature. Am J Hematol 1992;40:121-5.
20. Habibi B. Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol 1985;61:139-43.
21. Kramer MR, Levene C, Hershko C. Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy. Scand J Haematol 1986;36:118-20.
22. Shirey RS, Morton SJ, Lawton KB, et al. Fenoprofen-induced immune hemolysis. Difficulties in diagnosis and complications in compatibility testing. Am J Clin Pathol 1988;89:410-4.
23. Bell PM, Humphrey CA. Thrombocytopenia and haemolytic anaemia due to feprazone. Br Med J 1982;284:17.
24. Guidry JB, Ogburn CL Jr, Griffin FM Jr. Fatal autoimmune hemolytic anemia associated with ibuprofen. JAMA 1979;242:68-9.
25. Scott GL, Myles AB, Bacon PA. Autoimmune hemolytic anemia and mefenamic acid therapy. Br Med J 1968;3:534-5.
26. Andou S, Fujii S, Harada Y, et al. α-methyldopa-type autoimmune hemolytic anemia caused by lobenzarit disodium of a mefenamic acid derivative and immunomodulator (letter). Blood 1994;83:3097.
27. Hughes JA, Sudell W. Hemolytic anemia associated with naproxen (letter). Arthritis Rheum 1983;26:1054.
28. Johnson FP Jr, Hamilton HE, Liesch MR. Immune hemolytic anemia associated with sulindac. Arch Intern Med 1985;145:1515-6.
29. Angeles ML, Reid ME, Yacob UA, et al. Sulindac-induced immune hemolytic anemia. Transfusion 1994;34:255-8.
30. Van Dijk BA, Rico PB, Hoitsma A, Kunst VA. Immune hemolytic anemia associated with tolmetin and suprofen. Transfusion 1989;29:638-41.
31. Larsen JR, Becher JW. Fatal fulminant autoimmune haemolytic anaemia associated with tolmetin use and gastric carcinoma. Case report and literature review. Drug Safety 1993;8:169-78.
32. Schulenburg BJ, Beck ML, Pierce SR, et al. Immune hemolysis associated with Zomax (abstract). Transfusion 1983;23(Suppl):409.
33. Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;36:2-6.
34. Salama A, Shutz B, Kiefel V, et al. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 1989;72:127-32.
35. Stroncek DF, Vercellotti GM, Hammerschmidt DE, et al. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood 1992;80:241-8.
36. Meyer O, Gaedicke G, Salama A. Demonstration of drug-dependent antibodies in two patients with neutropenia and successful treatment with granulocyte-colony-stimulating factor. Transfusion 1999;39:527-30.
37. Weltzien HU, Moulon C, Martin S, et al. T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 1996;107:141-51.
38. Van Pelt FN, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Semin Liver Dis 1995;15:283-300.
39. Williams AM, Dickinson RG. Studies on the reactivity of acyl glucuronides-VI. Modulation of reversible and covalent interaction of diflunisal acyl glucuronide and its isomers with human plasma protein in vitro. Biochem Pharmacol 1994;47:457-67.
40. Zia-Amirhosseini P, Spahn-Langguth H. Benet LZ. Bioactivation by glucuronide-conjugate formation. Adv Pharmacol 1994;27:385-97.
41. Zia-Amirhosseini P, Harris RZ, Brodsky FM, Benet LZ. Hypersensitivity of nonsteroidal anti-inflammatory drugs. Nat Med 1995;1:2-4.